NEW YORK, Jan. 31 - CuraGen on Thursday reported that swelling research and development expenses managed to double its net loss in the fourth quarter, and the 2002 revenues would only reach 75 percent of 2001 revenues.

Loss in the period ended on Dec. 31 widened to $16.2 million, or 33 cents per share, compared with $8.6 million, or 21 cents per share, one year ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.